Market Cap : 447.28 M | Enterprise Value : 178.08 M | PE Ratio : At Loss | PB Ratio : 1.76 |
---|
NAS:ATRA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ATRA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Atara Biotherapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1. Operating Margin %Atara Biotherapeutics's Operating Margin % for the quarter that ended in Jun. 2022 was -62.30%. As of today, Atara Biotherapeutics's Piotroski F-Score is 4.
For the Biotechnology subindustry, Atara Biotherapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Atara Biotherapeutics's Profitability Rank falls into.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Atara Biotherapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Atara Biotherapeutics's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Jun. 2022 ) | / | Revenue (Q: Jun. 2022 ) |
= | -32.132 | / | 51.579 | |
= | -62.30 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Atara Biotherapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Thank you for viewing the detailed overview of Atara Biotherapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Yarema Kristin | officer: Chief Commercial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Murugan Amar | officer: SVP, GC & Secretary | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Dupont Jakob | officer: EVP, Head of R&D | C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063 |
Touchon Pascal | director, officer: President and CEO | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Koppikar Utpal | officer: Chief Financial Officer | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Mallik Ameet | director | C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102 |
Renaud Ronald C Jr | director | C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109 |
Seidenberg Beth C | director | |
Heiden William K | director | C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451 |
Dobmeier Eric | director | C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021 |
Roncarolo Maria Grazia | director | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Gallagher Carol Giltner | director | C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 |
Fust Matthew K | director | C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949 |
Baynes Roy D. | director | C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130 |
Berger Dietmar | officer: Global Head of R&D | C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 |
Other Sources
By Zacks 2022-02-24
By tipranks.com 2022-02-28
By Seekingalpha 2021-09-20
By Fool 2020-12-23
By Fool 2022-02-18
By Seekingalpha 2021-12-13
By Zacks 2021-11-10